Baseline characteristics
| Characteristic . | N . | % . | Median (range) . |
|---|---|---|---|
| Age, y | 38 | 50 (19-82) | |
| Gender, male | 29 | 76 | |
| Patients with prior therapies directed at CIDP or MPD, number patients treated | 22 | 58 | |
| Eastern Cooperative Oncology Group PS 2/3 | 12/11 | 31/29 | |
| Polyneuropathy | 38 | 100 | |
| Monoclonal plasma cell disorder | 38 | 100 | |
| VEGF, pg/mL | 19 | 375 (<32-3764) | |
| Castleman disease | 3 | 8 | |
| Organomegaly | 22 | 58 | |
| Lymphadenopathy | 16 | 42 | |
| Hepatomegaly | 6 | 16 | |
| Splenomegaly | 12 | 32 | |
| Endocrinopathy | 33 | 87 | |
| Serum immunoglobulin isotypes | NA | ||
| IgG/IgA | 27/7 | 71/18 | |
| κ/λ | 2/32 | 5/84 | |
| Nonsecretory | 4 | 11 | |
| Bone marrow | 38 | 100 | |
| Plasma cells, % | NA | 1 (1-20*) | |
| Polyclonal/monoclonal | 38/0* | 100/0* | |
| Skin involvement | 30 | 79 | |
| Papilledema | 5 | 13 | |
| DLCO, % predicted | 15 | 67 (34-108) | |
| RSVP, mm water | 11 | 34 (20-62) | |
| Thrombocytosis or erythrocytosis | 22 | 58 | |
| Extravascular volume overload | 31 | 82 | |
| Lower extremity edema | 28 | 74 | |
| Pericardial effusion | 3 | 8 | |
| Pleural effusion | 5 | 13 | |
| Ascites | 7 | 18 | |
| Bone lesions per patient | NA | 1 (1-6) | |
| Bone lesions with sclerosis | 35 | 92 | |
| Number of bone lesions in total† | 66 | ||
| Spine‡ | 19 | 29 | |
| Pelvis | 31 | 47 | |
| Long bone | 5 | 8 | |
| Rib, scapula, clavicle, or sternum | 11 | 17 |
| Characteristic . | N . | % . | Median (range) . |
|---|---|---|---|
| Age, y | 38 | 50 (19-82) | |
| Gender, male | 29 | 76 | |
| Patients with prior therapies directed at CIDP or MPD, number patients treated | 22 | 58 | |
| Eastern Cooperative Oncology Group PS 2/3 | 12/11 | 31/29 | |
| Polyneuropathy | 38 | 100 | |
| Monoclonal plasma cell disorder | 38 | 100 | |
| VEGF, pg/mL | 19 | 375 (<32-3764) | |
| Castleman disease | 3 | 8 | |
| Organomegaly | 22 | 58 | |
| Lymphadenopathy | 16 | 42 | |
| Hepatomegaly | 6 | 16 | |
| Splenomegaly | 12 | 32 | |
| Endocrinopathy | 33 | 87 | |
| Serum immunoglobulin isotypes | NA | ||
| IgG/IgA | 27/7 | 71/18 | |
| κ/λ | 2/32 | 5/84 | |
| Nonsecretory | 4 | 11 | |
| Bone marrow | 38 | 100 | |
| Plasma cells, % | NA | 1 (1-20*) | |
| Polyclonal/monoclonal | 38/0* | 100/0* | |
| Skin involvement | 30 | 79 | |
| Papilledema | 5 | 13 | |
| DLCO, % predicted | 15 | 67 (34-108) | |
| RSVP, mm water | 11 | 34 (20-62) | |
| Thrombocytosis or erythrocytosis | 22 | 58 | |
| Extravascular volume overload | 31 | 82 | |
| Lower extremity edema | 28 | 74 | |
| Pericardial effusion | 3 | 8 | |
| Pleural effusion | 5 | 13 | |
| Ascites | 7 | 18 | |
| Bone lesions per patient | NA | 1 (1-6) | |
| Bone lesions with sclerosis | 35 | 92 | |
| Number of bone lesions in total† | 66 | ||
| Spine‡ | 19 | 29 | |
| Pelvis | 31 | 47 | |
| Long bone | 5 | 8 | |
| Rib, scapula, clavicle, or sternum | 11 | 17 |
MPD, myeloproliferative disorder; RSVP, right ventricular systolic pressure; NA, not applicable/available.
There was 1 biclonal patient with iliac crest bone marrow containing clonal plasma cells not related to POEMS syndrome that instead related to concomitant smoldering multiple myeloma.
N refers to the number of lesions, not patients, and the percentage is calculated from total lesions.
Spine only includes cervical, thoracic, and lumbar regions.